recoflavone and Weight-Loss

recoflavone has been researched along with Weight-Loss* in 1 studies

Other Studies

1 other study(ies) available for recoflavone and Weight-Loss

ArticleYear
Effect of DA-6034, a derivative of flavonoid, on experimental animal models of inflammatory bowel disease.
    Archives of pharmacal research, 1999, Volume: 22, Issue:4

    Inflammatory bowel disease (IBD) is a multifactorial disorder with unknown etiology and pathogenesis. DA-6034, 7-carboxymethyloxy-3', 4', 5-trimethoxy flavone, is a synthetic flavonoid known to possess anti-inflammatory activity. This study was performed to evaluate the oral therapeutic effect of DA-6034 in three experimental animal models of IBD: two chemical-induced IBD models of rats and the human leukocyte antigen (HLA)-B27 transgenic rat model known to develop spontaneous colitis without the use of exogenous agents. Acute chemical colitis was induced by intracolonic instillation of 1.2 ml of 4% acetic acid solution. Prednisolone (1 mg/kg), sulfasalazine (100 mg/kg) and DA-6034 (0.3 to approximately 3 mg/kg) were orally administered twice daily for 6 days in these rats. In addition, chronic chemical colitis was induced by intracolonic administration of trinitrobenzene sulfonic acid (TNBS) 30 mg in 50% ethanol and agents were orally administered for 6 or 20 days. In chemical-induced IBD models, all of these agents reduced the severity of colitis and specially, DA-6034 (3 mg/kg) showed more potent effect than other drugs in macroscopic lesion score. In HLA-B27 transgenic rats, DA-6034 (3 mg/kg) and prednisolone (0.5 mg/kg) were treated orally twice daily for 6 weeks. The HLA-B27 transgenic rats showed only mild colitis, compared with the chemical-induced colitis models. DA-6034 ameliorated the loose stool and decreased microscopic damage, which is the important indicator of this model. In conclusion, oral therapy of DA-6034 attenuated the macroscopic and histologic damages of the colon in all three experimental models of IBD, which suggest that DA-6034 could be a promising drug in the treatment of IBD.

    Topics: Acetic Acid; Animals; Animals, Genetically Modified; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; beta 2-Microglobulin; Colitis; Flavonoids; Gastrointestinal Agents; HLA-B27 Antigen; Humans; Inflammatory Bowel Diseases; Organ Size; Prednisolone; Rats; Sulfasalazine; Trinitrobenzenesulfonic Acid; Weight Loss

1999